Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction. METHODS AND RESULTS: We conducted a systematic rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Toth, Peter P., Worthy, Gillian, Gandra, Shravanthi R., Sattar, Naveed, Bray, Sarah, Cheng, Lung‐I., Bridges, Ian, Worth, Gavin M., Dent, Ricardo, Forbes, Carol A., Deshpande, Sohan, Ross, Janine, Kleijnen, Jos, Stroes, Erik S. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Systematic Review and Meta‐Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721820/
https://www.ncbi.nlm.nih.gov/pubmed/28971955
http://dx.doi.org/10.1161/JAHA.116.005367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721820/
https://www.ncbi.nlm.nih.gov/pubmed/28971955
http://dx.doi.org/10.1161/JAHA.116.005367

Ejemplares similares